dfcicancerbio.bsky.social
@dfcicancerbio.bsky.social
Reposted
A new study led by Dipanjan Chowdhury, PhD, co-director of our Center for BRCA and Related Genes, uncovers why some cancers resist PARP inhibitors. The findings could help guide more personalized treatment strategies.

Learn more about the study: bit.ly/4ko5CAq
Double Negative in Cells Could Undermine PARP Inhibitors
Published: June 10, 2025Updated: June 11, 2025Written by: Beth DoughertyThere are two ways to fix things: the quick way and the careful one. In cancer, cells with BRCA1 mutations tend to choose the quick fix, leaving them vulnerable to medicines like PARP inhibitors.   PARP inhibitors cause DNA to break. When broken strands and sketchy repairs ... Read more
bit.ly
July 11, 2025 at 5:00 PM
Reposted
We are looking to hire an Assistant/Associate Professor interested in creating an innovative (and exciting) program of research in chemical biology, medicinal chemistry, ML/AI, drug discovery - all in the context of cancer biology!
careers.dana-farber.org/job/11813/as...
Faculty/Health Educator Job: Assistant/Associate Professor, Chemical Biology at Dana-Farber Cancer Institute in 450 Brookline Ave, Boston, MA
Assistant/Associate Professor, Chemical Biology job
careers.dana-farber.org
June 30, 2025 at 7:30 PM
Reposted
Congratulations Xin Gu, Ph.D., recipient of a Klingenstein Fellowship Award in Neuroscience for the project, "Elucidating the Role of the Midnolin-Proteasome Pathway in the Central Nervous System." @xingulab.bsky.social

xingulab.dana-farber.org
July 1, 2025 at 1:36 PM
Reposted
New research in @pnas.org led by @danafarber.bsky.social’s Yubao Wang, PhD, in the lab of Tom Roberts, PhD, explored an engineered, degradable form of a small viral protein and made new insights into a key cell growth pathway often hijacked by cancer cells.

Read more: bit.ly/4ezpMpE
July 7, 2025 at 3:55 PM
Reposted
In collaboration with Beth Israel Deaconess Medical Center, our new dedicated cancer hospital, projected to open in 2031, will strengthen Boston’s position as a global leader in oncology — and expand access to the most advanced care for patients across the region.

bit.ly/402eQej
Following State and City Approvals, New Cancer Hospital and Clinical Collaboration Enters Next Phase | Dana-Farber Cancer Institute
With the recent completion of a multi-agency, state and city regulatory process, the clinical collaboration among Dana-Farber Cancer Institute (Dana-Farber), Beth Israel Deaconess Medical Center (BIDMC) and Harvard Medical Faculty Physicians at BIDMC (HMFP) is moving forward. The collaboration will support a new Dana-Farber cancer hospital, and the joint clinical teams are developing comprehensive plans to transform cancer care around the world and push the boundaries of research and innovation.
bit.ly
July 8, 2025 at 4:00 PM
Reposted
quick reminder to join us tonight at @harvardmed.bsky.social for a great talk by Colby Ford @colby.tuple.xyz
Come learn about how to run the computational infrastructure that's powering the protein design revolution

July 9th 2025 at 7pm EDT in TMEC250 @harvardmed.bsky.social

"Model. Package. Deploy. Repeat: A DevOps Approach to Biomolecular Scalability"

Colby Ford @colby.tuple.xyz

bpdmc.org
schedule
introduction and membership Boston Protein Design and Modeling Club (BPDMC) is a community of computational protein engineers and modelers from both academia and industry. While we are based in Boston...
bpdmc.org
July 9, 2025 at 1:01 PM
Reposted
Congratulations Xin!!
A new study in Molecular Cell led by @danafarber.bsky.social’s Xin Gu, PhD, highlights midnolin as a key regulatory component of proteostasis in plasma cells and suggests that restoring or enhancing this pathway could represent a novel therapeutic avenue in myeloma treatment. bit.ly/4l8Zuwu
June 18, 2025 at 2:03 PM
Reposted
Thank you @shalinhnaik.bsky.social for participating in our NIC interview series! We really appreciate it 🤩
Honestly, am so honoured that the next generation of researchers selected me to speak. This was fun to record!
We're kicking off our Interview Spotlight Series with the 2025 New Investigator Invited Speaker @shalinhnaik.bsky.social‬ Prof. Naik dives into his current work, career inspirations and life outside of the lab. Watch the interview on www.simplyblood.org
June 2, 2025 at 5:15 PM
Reposted
Scooper Bowl® has officially kicked off at Boston City Hall Plaza! Join us now through Thursday, 12-8pm each day, for unlimited ice cream all to benefit @danafarber.bsky.social. 🍦🩷

🎟️: jimmyfund.gives/BSDay

#boston #bostonevents #bostonfoodies
June 3, 2025 at 6:28 PM
Reposted
NEW PREPRINT ALERT: Buhrlage lab in collaboration with @irinabezsonova.bsky.social has developed a new class of USP7 activators!

www.biorxiv.org/content/10.1...
Small-molecule allosteric activator of ubiquitin-specific protease 7 (USP7)
Ubiquitin-specific protease 7 (USP7) is a deubiquitylase essential for cell homeostasis, DNA repair, and regulation of both tumor suppressors and oncogenes. Inactivating USP7 mutations have been assoc...
www.biorxiv.org
May 8, 2025 at 4:27 PM
Reposted
Congrats to @danafarber.bsky.social’s Brian Wolpin, MD, MPH, a 2025 Giants of Cancer Care by @onclive.bsky.social. Dr. Wolpin is recognized for his remarkable achievements in #gastrointestinal and #pancreatic cancer research and clinical practice.

➡️ bit.ly/3RTq7ZS
May 8, 2025 at 4:30 PM
Reposted
188 PhD/graduate fellowships from private foundations, federal agencies and international organizations.

Database can be downloaded here: research.jhu.edu/rdt/funding-...
May 9, 2025 at 7:44 PM
Reposted
Congratulations to Eric Smith, MD, PhD, @danafarber.bsky.social on receiving the Outstanding New Investigator Award from @asgct.bsky.social. Smith will present on advancing CAR T cell therapy for cancer immunotherapy. #ASGCT2025
May 16, 2025 at 1:30 PM
Reposted
Happy #NationalNursesWeek! In this video, @danafarber.bsky.social’s Senior VP for Patient Care Services & CNO Anne Gross is joined by a patient’s mother and other members of the NPCS team in discussing what relationship-based care means to them. bit.ly/44U7WLc
May 6, 2025 at 8:30 PM
Reposted
Super excited to share a new preprint from our lab on design of small-molecule binding proteins using neural networks! The paper has a bit of everything. A new graph neural network, new design algorithms, and experimental validation. www.biorxiv.org/content/10.1...
🧵🧪
Zero-shot design of drug-binding proteins via neural selection-expansion
Computational design of molecular recognition remains challenging despite advances in deep learning. The design of proteins that bind to small molecules has been particularly difficult because it requ...
www.biorxiv.org
April 28, 2025 at 3:22 PM
Reposted
in case you missed the superb seminar that Ben Fry gave back in January, you can now check out the recording youtu.be/IgFgAYQrke4
and the preprint www.biorxiv.org/content/10.1...
Design of small molecule binding proteins using deep learning
YouTube video by Boston Protein Design and Modeling Club
youtu.be
May 3, 2025 at 2:07 PM
Reposted
GelGenie has finally been published in Nature Communications (DOI: doi.org/10.1038/s414...)!

GelGenie is a free, open-source app for the one-click extraction of band data from gel images using AI, all bundled within a cross-platform GUI that can be integrated in your workflow immediately. 🧬
May 5, 2025 at 1:38 PM
Reposted
Recently, the Mass Public Health Council voted unanimously to approve @danafarber.bsky.social’s plans to build a 300-bed cancer hospital in the Longwood Medical Area. Read more about how a stand-alone cancer hospital will increase equitable access to care: bit.ly/4jeqCcu
April 3, 2025 at 7:04 PM
Reposted
From the team of Angela Koehler and colleagues at MIT, an excellent analysis of how CDK9 degradation differs from CDK9 inhibition with respect to Myc regulation. Congratulations!
www.cell.com/cell-chemica...
Targeted degradation of CDK9 potently disrupts the MYC-regulated network
Toure et al. investigate a known challenge in CDK9 inhibition—the compensatory increase in MYC levels. They demonstrate that a selective CDK9 degrader with rapid kinetics circumvents this effect, prov...
www.cell.com
April 3, 2025 at 8:02 PM
Reposted
New preprint out co-led by Hannah Lloyd and Christina Woo at Harvard along with colleagues at the Broad and CeTPD Dundee gives insight on how to detect and discover native substrates of CRBN!
www.biorxiv.org/content/10.1...
A method for the detection and enrichment of endogenous cereblon substrates
C-Terminal cyclic imides are posttranslational modifications on proteins that are recognized and removed by the E3 ligase substrate adapter cereblon (CRBN). Despite the observation of these modificati...
www.biorxiv.org
April 3, 2025 at 8:35 PM
Reposted
Induced proximity modalities at the cell surface! Comprehensive review of emerging approaches and therapeutic possibilities by Carolyn Bertozzi and colleagues at Stanford!
www.nature.com/articles/s41...
Induced proximity at the cell surface - Nature Biotechnology
Technologies to modulate induced proximity at the cell surface advance the manipulation of diverse biological responses.
www.nature.com
April 3, 2025 at 8:55 PM
Reposted
Congratulations to @danafarbernews.bsky.social’s Matthew Meyerson, MD, PhD, FAACR, @drchoueiri.bsky.social, and Alice T. Shaw, MD, PhD, recipients of @theaacr.bsky.social 2025 Scientific Achievement Awards. bit.ly/4j7m8om
April 14, 2025 at 2:53 PM
Reposted
Congratulations to @danafarber.bsky.social’s Bradley Bernstein, MD, PhD, A. Thomas Look, MD, and William R. Sellers, MD, who have been elected as Fellows of @theaacr.bsky.social Academy Class of 2025. #AACRFellows bit.ly/41RE1Bs
March 10, 2025 at 4:50 PM